Apremilast in the Treatment of Uveitis

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT00889421
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    oral dose of 30 mg BID for 6 months

Study Details

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Key Dates

First listed
Apr 28, 2009
Start date
Nov 30, 2009
Status verified
Jun 2014
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Patients receiving apremilast.

Primary Outcome Measure

Improvement by 2 or More Lines of Best-corrected Snellen Visual Acuity in at Least One Eye [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health & Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health & Science University· Portland, OR

Related Studies